In 322 non-cirrhotic adults with chronic HCV in Malaysia, 8 weeks of sofosbuvir/ravidasvir was non-inferior to 12 weeks: SVR12 was 93.4% (142/152) vs 93.5% (143/153); adverse events were comparable and mostly mild.
RCTn = 322
Abu Hassan et al. A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial)